|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 155.40 EUR | -1.83% |
|
-0.96% | +30.59% |
| 08-04 | Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration | CI |
| 08-03 | Jefferies Downgrades Ipsen to Underperform, Boosts PT | MT |
MarketScreener Strategies
Search
 | Ipsen: Another quarterly beat; 2026 guidance upgraded | July 30, 2026 at 09:49 am |
 | Ipsen: Reassessing mid-term risks | July 06, 2026 at 08:00 am |
| Ipsen: Beneficiary of favourable product mix and imminent readouts | May 27, 2026 at 03:30 am |
| Ipsen: Opened the year with encouraging traction | April 23, 2026 at 05:04 pm |
| Ipsen: Markets applaud strong finish to 2025 and better-than-expected 2026 outlook | February 12, 2026 at 09:32 am |
| Ipsen raises 2025 outlook after stronger Somatuline | November 17, 2025 at 08:10 am |
No results match your criteria
- Stock Market
- Stocks
- IPN Stock
- News Ipsen
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
